Forget the State Pension, FTSE 100 dividend share AstraZeneca may be all you need

AstraZeneca plc (LON:AZN) (AZN.L) could become a top FTSE 100 (INDEXFTSE: UKX) income stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

With AstraZeneca (LSE: AZN) having failed to deliver dividend growth on a per share basis in the last five years, income investors may feel it is not an appealing dividend share. However, the company is now expected to generate rising profitability which could lead to a higher dividend.

As such, it could be a worthwhile income share at a time when the State Pension is becoming less desirable as the age at which it is paid increases.

Of course, there are other stocks which could offer improving dividend growth prospects. One example released positive news on Monday, which suggests it could offer high income returns.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Positive outlook

The company in question is engineering services group Renew (LSE: RNWH). It released a trading update ahead of its annual results, with it expected to report financial performance which is in line with expectations. It has been able to deliver good growth in operating profit, as well as a rising operating margin.

The company’s Engineering Services business is expected to have performed ahead of budget, with its order book having grown and the integration of QTS having moved ahead as planned. In the Specialist Building segment, a focus on selectivity has reduced the level of trading. However, it is expected to remain profitable.

With Renew forecast to post a 12% rise in earnings in the 2019 financial year, its price-to-earnings growth (PEG) ratio stands at just 1. This suggests that it offers a wide margin of safety, while dividend growth could also be on the horizon. With dividends being covered 3.5 times by profit, the company’s yield could move significantly higher from its current 2.8% level.

Changing business

The outlook for AstraZeneca also appears to be appealing from an income perspective. The company’s legacy issues from patent losses are set to continue in the current year, with earnings due to fall by 22%. Next year though, earnings growth of 13% is due to be reported. This has the potential to catalyse dividend growth for the first time in over five years.

In fact, dividends per share are expected to increase by 1.4% in 2019. This puts the stock on a forward yield of around 3.8%. With the potential for further dividend growth due to the investment the company is making in its pipeline, it could offer a higher yield than the FTSE 100 over the medium term. This could attract additional demand for the stock and help to lift its share price.

With AstraZeneca having a relatively defensive business model that is less correlated to the wider economy than many of its index peers, it could offer greater resilience when it comes to the payment of its dividend. Since its dividend cover currently stands at around 1.2, dividend growth could match profit growth over the coming years. As such, now could be the right time to buy it as its financial performance looks set to undergo a transformation over the coming years.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Here’s a high-potential stock to consider buying in July!

This company's undergoing a transition in order to make it a leaner and more focused business. Dr James Fox explores…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

In 12 months, a £10,000 investment in Legal & General shares could become…

If broker forecasts are accurate, Legal & General shares will deliver healthy capital gains and dividends over the next year.

Read more »

British Pennies on a Pound Note
Investing Articles

£5,000 invested in this 9p penny stock just 1 month ago is now worth…

This high-flying penny stock offers investors a lot of potential reward, as well as a fair bit of risk. Ben…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

After the FTSE 100 broke 9,000 points, does the UK market look overvalued?

The FTSE 100 went past 9,000 points this week but Mark Hartley says there are still bargains out there and…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Nvidia stock hit an all-time high this week. But could it be a bargain, even now?

After the Nvidia stock hit an all-time high this week, might it still be an attractive opportunity for our writer's…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As the FTSE 100 hits an all-time high, I’m following Warren Buffett’s advice!

Billionaire investor Warren Buffett is a font of stock market wisdom. Our writer reflects on his approach, as the FTSE…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

The FTSE 100 reached an all-time high this week. Is it too late to invest?

The FTSE 100 hit a new all-time high level over the past few days. Our writer explains why he thinks…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Here’s how £9,000 in savings could be used to target £343 a month of passive income

Christopher Ruane sets out a passive income plan that he reckons could help someone make sizeable sums over time without…

Read more »